Phaseline

Companies › Joincare Pharmaceutical Group Industry

Joincare Pharmaceutical Group Industry: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 1, 1 Phase 3; Respiratory, Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JKN2301 Dry Suspension
Neuraminidase inhibitor
–Phase 3Respiratory Viral Infection–
JKN24011–Phase 2COPD (Chronic Obstructive Pulmonary Disease)–
JKN2403–Phase 2COPD (Chronic Obstructive Pulmonary Disease)–
JKN2501–Phase 1Bacterial Infections–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07357051JKN2301 Dry SuspensionPhase 3Respiratory Viral InfectionInfectious diseaseJan 2026
NCT07207291JKN2501Phase 1Bacterial InfectionsInfectious diseaseMar 2026
NCT07440524JKN24011Phase 2COPD (Chronic Obstructive Pulmonary Disease)RespiratoryApr 2026
NCT07351734JKN2403Phase 2COPD (Chronic Obstructive Pulmonary Disease)RespiratorySep 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Mundipharma Research Thirty Respiratory Materia Medica Holding Shanghai Yidian Pharmaceutical Technology Development VivaVision Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.